Compare Incyte Corporation (INCY) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Nuwellis Inc — how do they compare? Incyte Corporation trades at $120.51 (market cap $24.54B), while Nuwellis Inc trades at $1.42 (market cap $542.80K). The key difference: Incyte Corporation is far larger — about 45210× Nuwellis Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| INCY | NUWE | |
|---|---|---|
Market Cap | $24.54B | $542.80K |
Sector | Health | Technology |
52-Week High | $129.93 | $220.50 |
52-Week Low | $81.61 | $1.42 |
Enterprise Value | $20.04B | -$1.27M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
NUWE trades at $1.41, down 0.7% on the day, with a bearish technical signal driven by moving averages. The company shows strong revenue growth, with preliminary Q2 2026 revenue up 14% year-over-year, but remains unprofitable with a net income margin of -217.22%. Recent developments include a reverse stock split, new CEO appointment, and expansion of its Aquadex platform into new pediatric markets. Cash flow from operations is negative, though recent financing activities have provided capital.
The outlook is mixed: growth initiatives and analyst support offer potential, but persistent losses and high cash burn pose significant risks. Investors should weigh the company's expansion against its financial sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
